Albireo Pharma (NASDAQ:ALBO) has announced that its investigational new drug application (IND) cleared the 30-day review from the US Food and Drug Administration and can proceed with a Phase 2 clinical trial of elobixibat to treat nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). As quoted in the press release: “The IND and subsequent … Continued
The post Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat appeared first on Investing News Network.